Skip to main navigation Skip to search Skip to main content

Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite

  • Michael Platten
  • , Peggy P. Ho
  • , Sawsan Youssef
  • , Paulo Fontoura
  • , Hideki Garren
  • , Eun Mi Hur
  • , Rohit Gupta
  • , Lowen Y. Lee
  • , Brian A. Kidd
  • , William H. Robinson
  • , Raymond A. Sobel
  • , Michael L. Selley
  • , Lawrence Steinman

Research output: Contribution to journalArticlepeer-review

399 Scopus citations

Abstract

Local catabolism of the amino acid tryptophan (Trp) by indoleamine 2,3-dioxygenase (IDO) is considered an important mechanism of regulating T cell immunity. We show that IDO transcription was increased when myelin-specific T cells were stimulated with tolerogenic altered self-peptides. Catabolites of Trp suppressed proliferation of myelin-specific T cells and inhibited production of proinflammatory T helper-1 (TH1) cytokines. N-(3,4,- Dimethoxycinnamoyl) anthranilic acid (3,4-DAA), an orally active synthetic derivative of the Trp metabolite anthranilic acid, reversed paralysis in mice with experimental autoimmune encephalomyelitis, a model of multiple sclerosis (MS). Trp catabolites and their derivatives offer a new strategy for treating TH1-mediated autoimmune diseases such as MS.

Original languageEnglish
Pages (from-to)850-855
Number of pages6
JournalScience
Volume310
Issue number5749
DOIs
StatePublished - 4 Nov 2005
Externally publishedYes

Fingerprint

Dive into the research topics of 'Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite'. Together they form a unique fingerprint.

Cite this